Amgen (AMGN) Deferred Taxes (2013 - 2026)
Amgen (AMGN) posted quarterly Deferred Taxes of -$176.0 million for Q1 2026, up 29.6% year-over-year from -$135.8 million in Q1 2025, and down 826.32% quarter-over-quarter from -$19.0 million in Q4 2025.
Amgen (AMGN) Deferred Taxes (2013 - 2026) Analysis & Trends
Amgen's Deferred Taxes history runs 14 years deep, the most recent figure standing at -$176.0 million for Q1 2026.
- In Q1 2026, Deferred Taxes rose 29.6% year-over-year to -$176.0 million; the TTM figure through Mar 2026 stood at -$647.0 million (up 39.93% YoY), while the FY2025 annual figure was -$721.0 million, up 41.29% from the prior year.
- Deferred Taxes for Q1 2026 stood at -$176.0 million, down from -$19.0 million in the prior quarter.
- The five-year high for Deferred Taxes was -$19.0 million in Q4 2025, with the low at -$623.0 million in Q4 2023.
- The 5-year median for Deferred Taxes is -$263.0 million (2022), against an average of -$270.4 million.
- The sharpest annual moves came in 2024 and 2025: Deferred Taxes slumped 718.37% in 2024, then jumped 94.31% in 2025.
- Amgen's Deferred Taxes stood at -$351.0 million in 2022, then slumped by 77.49% to -$623.0 million in 2023, then soared by 46.39% to -$334.0 million in 2024, then surged by 94.31% to -$19.0 million in 2025, then tumbled by 826.32% to -$176.0 million in 2026.
- Business Quant data shows AMGN's Deferred Taxes at -$176.0 million in Q1 2026, -$19.0 million in Q4 2025, and -$30.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -291.00 Mn |
| Mar 31, 2026 | -176.00 Mn |
| Dec 31, 2025 | -19.00 Mn |
| Sep 30, 2025 | -30.00 Mn |
| Jun 30, 2025 | -422.00 Mn |
| Mar 31, 2025 | -250.00 Mn |
| Dec 31, 2024 | -334.00 Mn |
| Sep 30, 2024 | -110.00 Mn |
| Jun 30, 2024 | -383.00 Mn |
| Mar 31, 2024 | -401.00 Mn |
| Dec 31, 2023 | -623.00 Mn |
| Sep 30, 2023 | -447.00 Mn |
| Jun 30, 2023 | -154.00 Mn |
| Mar 31, 2023 | -49.00 Mn |
| Dec 31, 2022 | -351.00 Mn |
| Sep 30, 2022 | -333.00 Mn |
| Jun 30, 2022 | -263.00 Mn |
| Mar 31, 2022 | -251.00 Mn |
| Dec 31, 2021 | -189.00 Mn |
| Sep 30, 2021 | -127.00 Mn |